skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 398,063  for All Library Resources

Sorted by: Sorted by: RelevanceOr hit Enter to replace sort method
Results 1 2 3 4 5 next page
Show only
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Vaccine protection against Zika virus from Brazil
Vaccine protection against Zika virus from Brazil
Material Type:
Article 		Add to My Research

Vaccine protection against Zika virus from Brazil

Nature (London), 2016-08, Vol.536 (7617), p.474-478 [Peer Reviewed Journal]

COPYRIGHT 2016 Nature Publishing Group ;COPYRIGHT 2016 Nature Publishing Group ;Copyright Nature Publishing Group Aug 25, 2016 ;ISSN: 0028-0836 ;EISSN: 1476-4687 ;DOI: 10.1038/nature18952 ;PMID: 27355570 ;CODEN: NATUAS

Full text available

Citations Cited by
2
Inactivated or Live-Attenuated Bivalent Vaccines That Confer Protection against Rabies and Ebola Viruses
Inactivated or Live-Attenuated Bivalent Vaccines That Confer Protection against Rabies and Ebola Viruses
Material Type:
Article 		Add to My Research

Inactivated or Live-Attenuated Bivalent Vaccines That Confer Protection against Rabies and Ebola Viruses

Journal of Virology, 2011-10, Vol.85 (20), p.10605-10616 [Peer Reviewed Journal]

2015 INIST-CNRS ;Copyright © 2011, American Society for Microbiology. All Rights Reserved. 2011 American Society for Microbiology ;ISSN: 0022-538X ;EISSN: 1098-5514 ;DOI: 10.1128/JVI.00558-11 ;PMID: 21849459

Full text available

Citations Cited by
3
Inactivated Rabies Virus-Based Ebola Vaccine Preserved by Vaporization Is Heat-Stable and Immunogenic Against Ebola and Protects Against Rabies Challenge
Inactivated Rabies Virus-Based Ebola Vaccine Preserved by Vaporization Is Heat-Stable and Immunogenic Against Ebola and Protects Against Rabies Challenge
Material Type:
Article 		Add to My Research

Inactivated Rabies Virus-Based Ebola Vaccine Preserved by Vaporization Is Heat-Stable and Immunogenic Against Ebola and Protects Against Rabies Challenge

The Journal of infectious diseases, 2019-11, Vol.220 (9), p.1521-1528 [Peer Reviewed Journal]

Published by Oxford University Press for the Infectious Diseases Society of America 2019. ;Published by Oxford University Press for the Infectious Diseases Society of America 2019. 2019 ;ISSN: 0022-1899 ;EISSN: 1537-6613 ;DOI: 10.1093/infdis/jiz332 ;PMID: 31374568

Full text available

Citations Cited by
4
Recent progress in mucosal vaccine development: potential and limitations
Recent progress in mucosal vaccine development: potential and limitations
Material Type:
Article 		Add to My Research

Recent progress in mucosal vaccine development: potential and limitations

Nature reviews. Immunology, 2012-08, Vol.12 (8), p.592-605 [Peer Reviewed Journal]

COPYRIGHT 2012 Nature Publishing Group ;COPYRIGHT 2012 Nature Publishing Group ;Copyright Nature Publishing Group Aug 2012 ;ISSN: 1474-1733 ;EISSN: 1474-1741 ;DOI: 10.1038/nri3251 ;PMID: 22828912

Full text available

Citations Cited by
5
Causal relationship between immunological responses and adverse reactions following vaccination
Causal relationship between immunological responses and adverse reactions following vaccination
Material Type:
Article 		Add to My Research

Causal relationship between immunological responses and adverse reactions following vaccination

Vaccine, 2019-01, Vol.37 (2), p.366-371 [Peer Reviewed Journal]

2018 ;Copyright © 2018. Published by Elsevier Ltd. ;Copyright Elsevier Limited Jan 7, 2019 ;ISSN: 0264-410X ;EISSN: 1873-2518 ;DOI: 10.1016/j.vaccine.2018.11.045 ;PMID: 30503656

Full text available

Citations Cited by
6
Immunogenicity and safety of MenACWY-TT, a meningococcal conjugate vaccine, co-administered with routine childhood vaccine in healthy infants: A phase III, randomized study
Immunogenicity and safety of MenACWY-TT, a meningococcal conjugate vaccine, co-administered with routine childhood vaccine in healthy infants: A phase III, randomized study
Material Type:
Article 		Add to My Research

Immunogenicity and safety of MenACWY-TT, a meningococcal conjugate vaccine, co-administered with routine childhood vaccine in healthy infants: A phase III, randomized study

Vaccine, 2018-06, Vol.36 (28), p.4102-4111 [Peer Reviewed Journal]

2018 ;Copyright © 2018. Published by Elsevier Ltd. ;Copyright Elsevier Limited Jun 27, 2018 ;ISSN: 0264-410X ;EISSN: 1873-2518 ;DOI: 10.1016/j.vaccine.2018.05.046 ;PMID: 29784470

Full text available

Citations Cited by
7
From research to phase III: Preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine
From research to phase III: Preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine
Material Type:
Article 		Add to My Research

From research to phase III: Preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine

Vaccine, 2011-09, Vol.29 (42), p.7229-7241 [Peer Reviewed Journal]

Elsevier Ltd ;2011 Elsevier Ltd ;Copyright © 2011 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Sep 23, 2011 ;ISSN: 0264-410X ;EISSN: 1873-2518 ;DOI: 10.1016/j.vaccine.2011.06.094 ;PMID: 21745521

Full text available

Citations Cited by
8
Concomitant administration of a fully liquid, ready-to-use DTaP-IPV-HB-PRP-T hexavalent vaccine with a meningococcal serogroup C conjugate vaccine in infants
Concomitant administration of a fully liquid, ready-to-use DTaP-IPV-HB-PRP-T hexavalent vaccine with a meningococcal serogroup C conjugate vaccine in infants
Material Type:
Article 		Add to My Research

Concomitant administration of a fully liquid, ready-to-use DTaP-IPV-HB-PRP-T hexavalent vaccine with a meningococcal serogroup C conjugate vaccine in infants

Vaccine, 2017-01, Vol.35 (3), p.452-458 [Peer Reviewed Journal]

2016 ;Crown Copyright © 2016. Published by Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Jan 11, 2017 ;ISSN: 0264-410X ;EISSN: 1873-2518 ;DOI: 10.1016/j.vaccine.2016.11.053 ;PMID: 27939054

Full text available

Citations Cited by
9
mRNA vaccine for cancer immunotherapy
mRNA vaccine for cancer immunotherapy
Material Type:
Article 		Add to My Research

mRNA vaccine for cancer immunotherapy

Molecular cancer, 2021-02, Vol.20 (1), p.41-41, Article 41 [Peer Reviewed Journal]

COPYRIGHT 2021 BioMed Central Ltd. ;2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2021 ;ISSN: 1476-4598 ;EISSN: 1476-4598 ;DOI: 10.1186/s12943-021-01335-5 ;PMID: 33632261

Full text available

Citations Cited by
10
Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial
Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial
Material Type:
Article 		Add to My Research

Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial

The Lancet (British edition), 2018-12, Vol.392 (10165), p.2718-2727 [Peer Reviewed Journal]

2018 Elsevier Ltd ;Copyright © 2018 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Dec 22, 2018 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(18)32488-7 ;PMID: 30409443

Full text available

Citations Cited by
11
BNT162b vaccines protect rhesus macaques from SARS-CoV-2
BNT162b vaccines protect rhesus macaques from SARS-CoV-2
Material Type:
Article 		Add to My Research

BNT162b vaccines protect rhesus macaques from SARS-CoV-2

Nature (London), 2021-04, Vol.592 (7853), p.283-289 [Peer Reviewed Journal]

Copyright Nature Publishing Group Apr 8, 2021 ;ISSN: 0028-0836 ;EISSN: 1476-4687 ;DOI: 10.1038/s41586-021-03275-y ;PMID: 33524990

Full text available

Citations Cited by
12
Novel vaccine technologies for the 21st century
Novel vaccine technologies for the 21st century
Material Type:
Article 		Add to My Research

Novel vaccine technologies for the 21st century

Nature reviews. Immunology, 2020-02, Vol.20 (2), p.87-88 [Peer Reviewed Journal]

COPYRIGHT 2020 Nature Publishing Group ;2019© This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2019 ;This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2019 ;ISSN: 1474-1733 ;EISSN: 1474-1741 ;DOI: 10.1038/s41577-019-0243-3 ;PMID: 31712767

Full text available

Citations Cited by
13
Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trial
Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trial
Material Type:
Article 		Add to My Research

Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trial

Vaccine, 2016-01, Vol.34 (3), p.313-319 [Peer Reviewed Journal]

Elsevier Ltd ;2015 Elsevier Ltd ;Copyright © 2015 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Jan 12, 2016 ;ISSN: 0264-410X ;EISSN: 1873-2518 ;DOI: 10.1016/j.vaccine.2015.11.056 ;PMID: 26657184

Full text available

Citations Cited by
14
Newcastle Disease Virus-Based Vectored Vaccine against Poliomyelitis
Newcastle Disease Virus-Based Vectored Vaccine against Poliomyelitis
Material Type:
Article 		Add to My Research

Newcastle Disease Virus-Based Vectored Vaccine against Poliomyelitis

Journal of virology, 2018-09, Vol.92 (17) [Peer Reviewed Journal]

Copyright © 2018 American Society for Microbiology. ;Copyright © 2018 American Society for Microbiology. 2018 American Society for Microbiology ;ISSN: 0022-538X ;EISSN: 1098-5514 ;DOI: 10.1128/JVI.00976-18 ;PMID: 29925653

Full text available

Citations Cited by
15
Immunogenicity and safety of a combined measles, mumps, rubella and varicella live vaccine (ProQuad® ) administered concomitantly with a booster dose of a hexavalent vaccine in 12–23-month-old infants
Immunogenicity and safety of a combined measles, mumps, rubella and varicella live vaccine (ProQuad® ) administered concomitantly with a booster dose of a hexavalent vaccine in 12–23-month-old infants
Material Type:
Article 		Add to My Research

Immunogenicity and safety of a combined measles, mumps, rubella and varicella live vaccine (ProQuad® ) administered concomitantly with a booster dose of a hexavalent vaccine in 12–23-month-old infants

Vaccine, 2015-05, Vol.33 (20), p.2379-2386 [Peer Reviewed Journal]

Elsevier Ltd ;2015 Elsevier Ltd ;Copyright © 2015 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited May 11, 2015 ;ISSN: 0264-410X ;EISSN: 1873-2518 ;DOI: 10.1016/j.vaccine.2015.02.070 ;PMID: 25765966

Full text available

Citations Cited by
16
Immunogenicity of a combination vaccine containing diphtheria toxoid, tetanus toxoid, three-component acellular pertussis, hepatitis B, inactivated polio virus, and Haemophilus influenzae type b when given concomitantly with 13-valent pneumococcal conjugate vaccine
Immunogenicity of a combination vaccine containing diphtheria toxoid, tetanus toxoid, three-component acellular pertussis, hepatitis B, inactivated polio virus, and Haemophilus influenzae type b when given concomitantly with 13-valent pneumococcal conjugate vaccine
Material Type:
Article 		Add to My Research

Immunogenicity of a combination vaccine containing diphtheria toxoid, tetanus toxoid, three-component acellular pertussis, hepatitis B, inactivated polio virus, and Haemophilus influenzae type b when given concomitantly with 13-valent pneumococcal conjugate vaccine

Vaccine, 2011-08, Vol.29 (35), p.6042-6048 [Peer Reviewed Journal]

Elsevier Ltd ;2011 Elsevier Ltd ;2015 INIST-CNRS ;Copyright © 2011 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Aug 11, 2011 ;ISSN: 0264-410X ;EISSN: 1873-2518 ;DOI: 10.1016/j.vaccine.2011.06.026 ;PMID: 21704105 ;CODEN: VACCDE

Full text available

Citations Cited by
17
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Material Type:
Article 		Add to My Research

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

New England Journal of Medicine, 2020-12, Vol.383 (27), p.2603-2615 [Peer Reviewed Journal]

Copyright © 2020 Massachusetts Medical Society. All rights reserved. ;Copyright © 2020 Massachusetts Medical Society. ;COPYRIGHT 2020 Massachusetts Medical Society ;2020. Not withstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.nejm.org/about-nejm/permissions?query=footer ;Copyright © 2020 Massachusetts Medical Society. All rights reserved. 2020 Massachusetts Medical Society ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2034577 ;PMID: 33301246

Digital Resources/Online E-Resources

Citations Cited by
18
Current status of COVID‐19 (pre)clinical vaccine development
Current status of COVID‐19 (pre)clinical vaccine development
Material Type:
Article 		Add to My Research

Current status of COVID‐19 (pre)clinical vaccine development

Angewandte Chemie International Edition, 2020-10 [Peer Reviewed Journal]

2020. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://novel-coronavirus.onlinelibrary.wiley.com ;DOI: 10.1002/anie.202008319

Digital Resources/Online E-Resources

Citations Cited by
19
Developing a low-cost and accessible COVID-19 vaccine for global health
Developing a low-cost and accessible COVID-19 vaccine for global health
Material Type:
Article 		Add to My Research

Developing a low-cost and accessible COVID-19 vaccine for global health

PLoS neglected tropical diseases, 2020-07, Vol.14 (7), p.e0008548 [Peer Reviewed Journal]

COPYRIGHT 2020 Public Library of Science ;COPYRIGHT 2020 Public Library of Science ;2020 Hotez, Bottazzi. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2020 Hotez, Bottazzi 2020 Hotez, Bottazzi ;ISSN: 1935-2735 ;ISSN: 1935-2727 ;EISSN: 1935-2735 ;DOI: 10.1371/journal.pntd.0008548 ;PMID: 32726304

Full text available

Citations Cited by
20
Kinetics of Antibody Persistence following Administration of a Combination Meningococcal Serogroup C and Haemophilus influenzae Type b Conjugate Vaccine in Healthy Infants in the United Kingdom Primed with a Monovalent Meningococcal Serogroup C Vaccine
Kinetics of Antibody Persistence following Administration of a Combination Meningococcal Serogroup C and Haemophilus influenzae Type b Conjugate Vaccine in Healthy Infants in the United Kingdom Primed with a Monovalent Meningococcal Serogroup C Vaccine
Material Type:
Article 		Add to My Research

Kinetics of Antibody Persistence following Administration of a Combination Meningococcal Serogroup C and Haemophilus influenzae Type b Conjugate Vaccine in Healthy Infants in the United Kingdom Primed with a Monovalent Meningococcal Serogroup C Vaccine

Clinical and Vaccine Immunology, 2010-01, Vol.17 (1), p.154-159 [Peer Reviewed Journal]

Copyright © 2010, American Society for Microbiology 2010 ;ISSN: 1556-6811 ;ISSN: 1556-679X ;EISSN: 1556-679X ;DOI: 10.1128/CVI.00384-09 ;PMID: 19906895

Full text available

Citations Cited by

Results 1 - 20 of 398,063  for All Library Resources

Sorted by: Sorted by: RelevanceOr hit Enter to replace sort method
Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Show only

  1. Peer-reviewed Journals (259,195)

Refine My Results

Creation Date 

From To
Refine
  1. Before 1959  (2,334)
  2. 1959 To 1974  (5,937)
  3. 1975 To 1990  (14,568)
  4. 1991 To 2007  (88,577)
  5. After 2007  (286,749)
  6. More options open sub menu

Subject 

  1. Vaccines  (213,893)
  2. Science & Technology  (211,408)
  3. Life Sciences & Biomedicine  (192,947)
  4. Humans  (137,574)
  5. Immunization  (82,967)
  6. Immunology  (79,802)
  7. Vaccination  (74,868)
  8. Animals  (73,381)
  9. Coronaviruses  (63,497)
  10. Female  (61,377)
  11. Covid-19 Vaccines  (55,727)
  12. Infectious Diseases  (54,175)
  13. Covid-19  (51,600)
  14. Infections  (45,273)
  15. Microbiology  (45,092)
  16. Pandemics  (42,894)
  17. Male  (42,528)
  18. Biological And Medical Sciences  (41,646)
  19. Public Health  (38,188)
  20. Medicine, Research & Experimental  (38,146)
  21. More options open sub menu

Language 

  1. English  (388,627)
  2. Japanese  (21,061)
  3. French  (5,506)
  4. Portuguese  (2,826)
  5. Spanish  (2,369)
  6. German  (1,177)
  7. Russian  (706)
  8. Norwegian  (365)
  9. Chinese  (317)
  10. Swedish  (309)
  11. Korean  (294)
  12. Turkish  (220)
  13. Finnish  (204)
  14. Italian  (177)
  15. Polish  (151)
  16. Persian  (145)
  17. Catalan  (70)
  18. Czech  (48)
  19. Croatian  (48)
  20. Indonesian  (47)
  21. More options open sub menu

Journal Title 

  1. Bmj  (4,640)
  2. Cheminform  (18,339)
  3. Human Vaccines & Immunotherapeutics  (5,265)
  4. New York Times  (15,932)
  5. Plos One  (9,085)
  6. The Journal Of Infectious Diseases  (4,786)
  7. The Lancet  (4,842)
  8. The Washington Post  (8,779)
  9. Vaccine  (27,759)
  10. Vaccines  (6,609)
  11. More options open sub menu
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait